Rigel Pharmaceuticals | RIGL - Trade Creditors


Rigel Pharmaceuticals reported $3.85M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agenus USD 71.08M 11.9M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Anika Therapeutics USD 6.34M 298K Mar/2026
Arrowhead Research USD 30.75M 2.19M Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Celldex Therapeutics USD 10.36M 9.18M Mar/2026
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
Ligand Pharmaceuticals USD 37.11M 33.87M Mar/2026
MacroGenics USD 4.29M 500K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Veracyte USD 6.91M 2.32M Mar/2026